Teva Looks to Diversify its Branded Drugs Portfolio with US$6.8 B Cephalon Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 5 (Table of Contents)
Published: 9 May-2011
DOI: 10.3833/pdr.v2011.i5.1468 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Teva Pharmaceutical Industries has outbid Valeant Pharmaceuticals by agreeing to acquire Cephalon for US$81...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS